share_log

Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight, Raises Price Target to $23

Benzinga ·  Oct 30, 2023 12:58

Piper Sandler analyst Christopher Raymond upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight and raises the price target from $18 to $23.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment